Thermo Fisher Scientific Inc. (NYSE:TMO – Get Rating) CEO Marc N. Casper sold 10,000 shares of the stock in a transaction on Thursday, August 4th. The shares were sold at an average price of $589.76, for a total value of $5,897,600.00. Following the completion of the sale, the chief executive officer now owns 183,373 shares of the company’s stock, valued at $108,146,060.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Thermo Fisher Scientific Price Performance
Shares of NYSE TMO opened at $590.26 on Friday. Thermo Fisher Scientific Inc. has a fifty-two week low of $497.83 and a fifty-two week high of $672.34. The stock has a market cap of $231.06 billion, a price-to-earnings ratio of 31.41, a PEG ratio of 1.83 and a beta of 0.83. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.13 and a current ratio of 1.65. The firm’s 50-day simple moving average is $549.03 and its 200 day simple moving average is $557.79.
Thermo Fisher Scientific (NYSE:TMO – Get Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical research company reported $5.51 earnings per share for the quarter, beating the consensus estimate of $4.92 by $0.59. Thermo Fisher Scientific had a net margin of 17.37% and a return on equity of 24.36%. The business had revenue of $10.97 billion for the quarter, compared to analysts’ expectations of $9.95 billion. During the same quarter last year, the firm earned $5.60 EPS. The firm’s revenue for the quarter was up 18.3% compared to the same quarter last year. As a group, research analysts anticipate that Thermo Fisher Scientific Inc. will post 22.92 earnings per share for the current fiscal year.
Thermo Fisher Scientific Announces Dividend
Hedge Funds Weigh In On Thermo Fisher Scientific
Several hedge funds have recently modified their holdings of the company. Vanguard Group Inc. lifted its position in shares of Thermo Fisher Scientific by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 31,457,999 shares of the medical research company’s stock worth $18,580,667,000 after buying an additional 354,211 shares in the last quarter. BlackRock Inc. lifted its position in shares of Thermo Fisher Scientific by 3.8% during the 4th quarter. BlackRock Inc. now owns 30,982,611 shares of the medical research company’s stock worth $20,672,838,000 after buying an additional 1,143,333 shares in the last quarter. State Street Corp lifted its position in shares of Thermo Fisher Scientific by 3.4% during the 4th quarter. State Street Corp now owns 16,223,173 shares of the medical research company’s stock worth $10,828,875,000 after buying an additional 529,712 shares in the last quarter. Capital Research Global Investors lifted its position in shares of Thermo Fisher Scientific by 2.3% during the 4th quarter. Capital Research Global Investors now owns 9,454,032 shares of the medical research company’s stock worth $6,308,097,000 after buying an additional 208,075 shares in the last quarter. Finally, Geode Capital Management LLC increased its stake in shares of Thermo Fisher Scientific by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 6,403,805 shares of the medical research company’s stock worth $4,261,136,000 after purchasing an additional 214,375 shares during the last quarter. Institutional investors own 87.48% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts have weighed in on TMO shares. Wells Fargo & Company downgraded Thermo Fisher Scientific from an “equal weight” rating to an “underweight” rating and decreased their price target for the stock from $605.00 to $525.00 in a report on Monday, April 25th. Morgan Stanley increased their price target on Thermo Fisher Scientific from $670.00 to $678.00 and gave the stock an “overweight” rating in a report on Friday, July 29th. SVB Leerink increased their price target on Thermo Fisher Scientific from $630.00 to $650.00 and gave the stock an “outperform” rating in a report on Friday, July 29th. Finally, Barclays increased their price target on Thermo Fisher Scientific from $630.00 to $685.00 and gave the stock an “overweight” rating in a report on Monday, August 1st. One analyst has rated the stock with a sell rating, two have assigned a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $661.08.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.
- Get a free copy of the StockNews.com research report on Thermo Fisher Scientific (TMO)
- MarketBeat: Week in Review 8/1 – 8/5
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Cronos Group Inc’s Revenues Are Up, Is It Time to Buy?
- Beyond Meat Is Not Beyond Hope, And It’s Cheap
- Why Apple Could Be At All-Time Highs By Year End
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.